camptothecin has been researched along with Neuroendocrine Tumors in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Assenat, E; Bouarioua, N; Cadiot, G; Coriat, R; Dahan, L; Dubreuil, O; Elhajbi, F; Ferru, A; Gangloff, A; Granger, V; Hautefeuille, V; Hentic, O; Kurtz, JE; Le Malicot, K; Lepage, C; Lepere, C; Lievre, A; Lombard-Bohas, C; Malka, D; Roquin, G; Scoazec, JY; Smith, D; Walter, T | 1 |
| Bengrine, L; Collot, T; Fumet, JD; Ghiringhelli, F; Klopfenstein, Q; Vincent, J | 1 |
| Barriuso, J; Borbath, I; Chougnet, CN; Crespo, G; Heetfeld, M; O'Toole, D; Olsen, IH; Pavel, M; Rinke, A; Walter, T | 1 |
| Coy, DH; Fuselier, JA; Mackey, LV; Qian, Q; Sun, G; Sun, L; Yu, CY | 1 |
| Gao, J; Gong, J; Li, J; Li, Y; Li, Z; Liu, Y; Lu, M; Lu, Z; Shen, L; Wang, X; Yang, L; Zhang, X; Zhou, J | 1 |
| Gress, TM; Rinke, A | 1 |
| Endo, M; Igawa, S; Ito, I; Kaira, K; Kameya, T; Murakami, H; Naito, T; Nakamura, Y; Takahashi, T; Tsuya, A; Watanabe, R; Yamamoto, N | 1 |
| Baba, H; Hayashi, N; Hirashima, K; Hiyoshi, Y; Nagai, Y; Sakamoto, Y; Sato, N; Shigaki, H; Suyama, K; Toyama, E; Watanabe, M; Yoshida, N | 1 |
| Ando, T; Fujinami, H; Hasumoto, Y; Hosokawa, A; Itaya, Y; Kajiura, S; Miyazaki, T; Nishikawa, J; Ogawa, K; Sugiyama, T; Suzuki, N; Ueda, A; Yamawaki, H | 1 |
| Bedenne, L; Bonnetain, F; Brixi-Benmansour, H; Cadiot, G; Hentic, O; Jouve, JL; Landi, B; Mitry, E | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Ryan, DP; Wu, B; Zhu, AX | 1 |
| Ahuja, G; Choudhry, I; Cuellar, S; Setty, S; Villano, JL; Yao, M | 1 |
1 review(s) available for camptothecin and Neuroendocrine Tumors
| Article | Year |
|---|---|
Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Gastrointestinal Neoplasms; Humans; Irinotecan; Ki-67 Antigen; Neoplasm Grading; Neuroendocrine Tumors; Practice Guidelines as Topic; Prognosis; Treatment Outcome | 2017 |
4 trial(s) available for camptothecin and Neuroendocrine Tumors
| Article | Year |
|---|---|
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Neuroendocrine; Drug Administration Schedule; Female; Fluorouracil; France; Humans; Intestinal Neoplasms; Leucovorin; Male; Neuroendocrine Tumors; Pancreatic Neoplasms; Research Design; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2018 |
Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Cisplatin; Female; Humans; Induction Chemotherapy; Intestinal Neoplasms; Irinotecan; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2017 |
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Treatment Outcome | 2011 |
A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Digestive System Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Massachusetts; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Survival Analysis; Treatment Outcome | 2006 |
7 other study(ies) available for camptothecin and Neuroendocrine Tumors
| Article | Year |
|---|---|
Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neuroendocrine Tumors; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Etoposide; Female; Fluorouracil; Humans; Ki-67 Antigen; Leucovorin; Male; Middle Aged; Neuroendocrine Tumors; Organoplatinum Compounds; Pancreatic Neoplasms; Prognosis; Survival Analysis; Young Adult | 2015 |
Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II.
Topics: Animals; Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Mice; Mice, Nude; Neuroendocrine Tumors; Pancreatic Neoplasms; Peptides; Receptors, Notch; Receptors, Peptide; Receptors, Somatostatin; Repressor Proteins; Signal Transduction; Valproic Acid | 2016 |
Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Platinum Compounds; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2010 |
Neuroendocrine tumor of the rectum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Colonoscopy; Diagnosis, Differential; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neuroendocrine Tumors; Pelvic Exenteration; Rectal Neoplasms | 2009 |
Esophageal small-cell carcinoma with syndrome of inappropriate secretion of antidiuretic hormone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplasms; Fatal Outcome; Humans; Hyponatremia; Inappropriate ADH Syndrome; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Paraneoplastic Endocrine Syndromes | 2011 |
Complete response of CNS-involved olfactory neuroendocrine tumor using multimodal therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cisplatin; Ethmoid Bone; Humans; Irinotecan; Male; Neuroendocrine Tumors; Organization and Administration; Radiotherapy, Adjuvant; Skull Neoplasms | 2008 |